Zantac settlements

Last updated

Ranitidine, a heartburn medicine sold under the brand name Zantac among others, was pulled from shelves in 2019, [1] following disclosure [2] of potential carcinogenic effects, [3] [4] which its manufacturers were accused of "engaging in a decades-long scheme to conceal." [5]

Contents

By 2020, the US Food and Drug Administration was telling consumers to discard whatever Zantac they still had. [6]

Overview

Zantac was first marketed in 1981, [7] and it was described in 1989 as "one of the most expensive drugs on the market", [8] and "the world's biggest-selling prescription drug". [9] Addiction to taking it ("a habit") was how some of its users described Zantac. [10] The focus of Glaxo, its manufacturer, was to gain market share "from Zantac competitors like Tagamet." [9] Cimetidine, sold under the brand name Tagamet among others, was listed in 2020 as an alternative to Zantac. [11]

The company also introduced a half-strength [12] Line Extension named Zantac 75. [13] The Los Angeles Times headlined "Public Faces Overdose of Similar Drug Names." [14]

The market for Zantac [15] and its competitors was described in 2005 as 13.5 billion US dollars. [16]

The product's problem was described by The New York Times as being "that a potential cancer-causing contaminant can build up in the drug when stored for long periods." [6] Heavy marketing expenditures resulted in Zantac being consumed by those who might have satisficed with less harmful alternatives. [9] As the potential harmful effects were identified, lawsuits were filed.

Oversight

By the time of the FDA's 1983 provisional approval for Zantac, it had already been approved for sale in 31 countries. [17] Marketing expenditures were measured by hundreds of millions of dollars. [18] [13] [19]

The 2019 New York Times headline "Heartburn Drugs Can Lead to Fatal Heart or Kidney Disease" [20] was a herald for Zantac being pulled from store shelves. [1]

Infants and children

A lower dose version of Zantac [9] had been given to children. A liquid form for ingestion by infants also had been marketed. [6]

Lawsuits

By 2022, a wave of Class action lawsuits was underway, and illegal robocalls were being made, even to those registered on the Federal Do-Not-Call list regarding settlement options.[ citation needed ] Also by then, "a wave of recalls" had taken place. [21]

Some of the lawsuits, which by October 2021 included over 100,000 plaintiffs, [5] were filed due to impending statute of limitations laws; estimates of how many people used Zantac have been given as high as 15 million.[ citation needed ] Facets of the legal rangling included:

Related to courtroom action were offers for a cash advance on impending settlements. Another money matter related to lawsuits and impending settlements is market timing. [24]

In June 2023, GSK reached a confidential settlement for one of the lawsuits related to Zantac causing cancer. [25] [26]

Zantac pill switching settlements

In 2008 settlements were reached regarding switching Medicaid patients taking Zantac from capsules to the "more costly" tablet form. [27] [28]

See also

Related Research Articles

<span class="mw-page-title-main">GSK plc</span> UK healthcare company

GSK plc is a British multinational pharmaceutical and biotechnology company with global headquarters in London. Established in 2000 by a merger of Glaxo Wellcome and SmithKline Beecham, GSK is the tenth largest pharmaceutical company and #294 on the 2022 Fortune Global 500, ranked behind other pharmaceutical companies China Resources, Sinopharm, Johnson & Johnson, Pfizer, Roche, AbbVie, Novartis, Bayer, and Merck Sharp & Dohme.

H<sub>2</sub> receptor antagonist Class of medications

H2 antagonists, sometimes referred to as H2RAs and also called H2 blockers, are a class of medications that block the action of histamine at the histamine H2 receptors of the parietal cells in the stomach. This decreases the production of stomach acid. H2 antagonists can be used in the treatment of dyspepsia, peptic ulcers and gastroesophageal reflux disease. They have been surpassed by proton pump inhibitors (PPIs). The PPI omeprazole was found to be more effective at both healing and alleviating symptoms of ulcers and reflux oesophagitis than the H2 blockers ranitidine and cimetidine.

Sanofi S.A. is a French multinational pharmaceutical and healthcare company headquartered in Paris, France. The corporation was established in 1973 and merged with Synthélabo in 1999 to form Sanofi-Synthélabo. In 2004, Sanofi-Synthélabo merged with Aventis and renamed to Sanofi-Aventis, which were each the product of several previous mergers. It changed its name back to Sanofi in May 2011. The company is a component of the Euro Stoxx 50 stock market index.

<span class="mw-page-title-main">Rosiglitazone</span> Chemical compound

Rosiglitazone is an antidiabetic drug in the thiazolidinedione class. It works as an insulin sensitizer, by binding to the PPAR in fat cells and making the cells more responsive to insulin. It is marketed by the pharmaceutical company GlaxoSmithKline (GSK) as a stand-alone drug or for use in combination with metformin or with glimepiride. First released in 1999, annual sales peaked at approximately $2.5-billion in 2006; however, following a meta-analysis in 2007 that linked the drug's use to an increased risk of heart attack, sales plummeted to just $9.5-million in 2012. The drug's patent expired in 2012.

<span class="mw-page-title-main">Irbesartan</span> Chemical compound

Irbesartan, sold under the brand name Avapro among others, is a medication used to treat high blood pressure, heart failure, and diabetic kidney disease. It is a reasonable initial treatment for high blood pressure. It is taken by mouth. Versions are available as the combination irbesartan/hydrochlorothiazide.

<span class="mw-page-title-main">Cefuroxime</span> Antibiotic medication

Cefuroxime, sold under the brand name Zinacef among others, is a second-generation cephalosporin antibiotic used to treat and prevent a number of bacterial infections. These include pneumonia, meningitis, otitis media, sepsis, urinary tract infections, and Lyme disease. It is used by mouth or by injection into a vein or muscle.

<span class="mw-page-title-main">Alosetron</span> Medication

Alosetron, sold under the brand name Lotronex among others, is a 5-HT3 antagonist used for the management of severe diarrhea-predominant irritable bowel syndrome (IBS) in females only.

<span class="mw-page-title-main">Ranitidine</span> Medication that decreases stomach acid

Ranitidine, sold under the brand name Zantac among others, is a medication used to decrease stomach acid production. It is commonly used in treatment of peptic ulcer disease, gastroesophageal reflux disease, and Zollinger–Ellison syndrome. It can be given by mouth, injection into a muscle, or injection into a vein. In September 2019, the probable carcinogen N-nitrosodimethylamine (NDMA) was discovered in ranitidine products from a number of manufacturers, resulting in recalls.

<span class="mw-page-title-main">Exelixis</span> American biotechnology company

Exelixis, Inc. is a genomics-based drug discovery company located in Alameda, California, and the producer of Cometriq, a treatment approved by the U.S. Food and Drug Administration (FDA) for medullary thyroid cancer with clinical activity in several other types of metastatic cancer.

<span class="mw-page-title-main">Off-label use</span> Use of pharmaceuticals for conditions different from that for which they were approved

Off-label use is the use of pharmaceutical drugs for an unapproved indication or in an unapproved age group, dosage, or route of administration. Both prescription drugs and over-the-counter drugs (OTCs) can be used in off-label ways, although most studies of off-label use focus on prescription drugs.

Dr. Reddy's Laboratories is an Indian multinational pharmaceutical company based in Hyderabad. The company was founded by Kallam Anji Reddy, who previously worked in the mentor institute Indian Drugs and Pharmaceuticals Limited. Dr. Reddy manufactures and markets a wide range of pharmaceuticals in India and overseas. The company produces over 190 medications, 60 active pharmaceutical ingredients (APIs) for drug manufacture, diagnostic kits, critical care, and biotechnology.

Sanofi Pasteur is the vaccines division of the French multinational pharmaceutical company Sanofi. Sanofi Pasteur is the largest company in the world devoted entirely to vaccines. It is one of four global producers of the yellow fever vaccine.

<span class="mw-page-title-main">Apotex</span> Canadian pharmaceutical company

Apotex Inc. is a Canadian pharmaceutical corporation. Founded in 1974 by Barry Sherman, the company is the largest producer of generic drugs in Canada, with annual sales exceeding CA$2.5 billion. By 2023, Apotex employed close to 8,000 people as Canada's largest drug manufacturer, with over 300 products selling in over 115 countries. Apotex manufactures and distributes generic medications for a range of diseases and health conditions that include cancer, diabetes, high cholesterol, glaucoma, infections and blood pressure.

Cervarix is a vaccine against certain types of cancer-causing human papillomavirus (HPV).

<i>N</i>-Nitrosodimethylamine Chemical compound

N-Nitrosodimethylamine (NDMA), also known as dimethylnitrosamine (DMN), is an organic compound with the formula (CH3)2NNO. It is one of the simplest members of a large class of N-nitrosamines. It is a volatile yellow oil. NDMA has attracted wide attention as being highly hepatotoxic and a known carcinogen in laboratory animals.

Pharmaceutical fraud involves activities that result in false claims to insurers or programs such as Medicare in the United States or equivalent state programs for financial gain to a pharmaceutical company. There are several different schemes used to defraud the health care system which are particular to the pharmaceutical industry. These include: Good Manufacturing Practice (GMP) Violations, Off Label Marketing, Best Price Fraud, CME Fraud, Medicaid Price Reporting, and Manufactured Compound Drugs. Examples of fraud cases include the GlaxoSmithKline $3 billion settlement, Pfizer $2.3 billion settlement, and Merck $650 million settlement. Damages from fraud can be recovered by use of the False Claims Act, most commonly under the qui tam provisions which rewards an individual for being a "whistleblower", or relator (law).

<span class="mw-page-title-main">Study 329</span> Scientific article

Study 329 was a clinical trial which was conducted in North America from 1994 to 1998 to study the efficacy of paroxetine, an SSRI anti-depressant, in treating 12- to 18-year-olds diagnosed with major depressive disorder. Led by Martin Keller, then professor of psychiatry at Brown University, and funded by the British pharmaceutical company SmithKline Beecham—known since 2000 as GlaxoSmithKline (GSK)—the study compared paroxetine with imipramine, a tricyclic antidepressant, and placebo. SmithKline Beecham had released paroxetine in 1991, marketing it as Paxil in North America and Seroxat in the UK. The drug attracted sales of $11.7 billion in the United States alone from 1997 to 2006, including $2.12 billion in 2002, the year before it lost its patent.

Belantamab mafodotin, sold under the brand name Blenrep, is a medication for the treatment of relapsed and refractory multiple myeloma.

Valisure is an American independent laboratory focused on the testing the purity and safety of pharmaceutical drugs and consumer products. Valisure was founded in 2015 in New Haven.

References

  1. 1 2 Sandra E. Garcia (September 30, 2019). "Zantac Pulled From Shelves by Walgreens, Rite Aid and CVS Over Carcinogen Fears". The New York Times . Retrieved July 4, 2022.
  2. ↑ Sanofi Provides Update on Precautionary Voluntary Recall of Zantac OTC in U.S., October 23, 2019
  3. ↑ Katie Thomas; Sheila Kaplan (September 13, 2019). "Zantac Has Low Levels of a Cancer-Causing Chemical". The New York Times . Retrieved July 4, 2022.
  4. ↑ Katie Thomas (October 18, 2019). "Zantac Recall Widens as Sanofi Pulls Its Drug Over Carcinogen Fears". The New York Times . Retrieved July 4, 2022.
  5. 1 2 3 Nate Raymond (October 7, 2021). "Sanofi, GSK can't escape Zantac proposed class actions, judge rules". Reuters . Retrieved July 4, 2022.
  6. 1 2 3 Katie Thomas (April 1, 2020). "Zantac Products Should Not Be Sold or Used, F.D.A. Warns, Citing Cancer Danger". The New York Times . Retrieved July 4, 2022.
  7. ↑ Steve Lohr (March 31, 1986). "Ulcer Drug Succeeds, but GLAXO Won't Relax". The New York Times . Retrieved July 4, 2022.
  8. ↑ Elsie Dragonetti (June 18, 1989). "The Zantac Saga Includes the Cost". The New York Times . Retrieved July 4, 2022.
  9. 1 2 3 4 Steven Prokesch (October 11, 1989). "Glaxo's Search: Son of Zantac". The New York Times . Retrieved July 4, 2022.
  10. ↑ "Reader Responses". The New York Times . October 18, 2006.
  11. ↑ Christina Caron (April 18, 2020). "Should Pregnant Women Avoid Zantac?". The New York Times . Retrieved July 4, 2022.
  12. ↑ "No Prescription Needed: Zantac, the ulcer medicine". The Los Angeles Times . December 22, 1995. Retrieved July 4, 2022.
  13. 1 2 Stuart Elliott (April 23, 1996). "Madison Avenue girds itself for Z-Day today". The New York Times . Retrieved July 4, 2022. with a budget estimated at $100 million -- for Zantac
  14. ↑ "Public Faces Overdose of Similar Drug Names". The Los Angeles Times . November 18, 1994. Quick, what was that prescription your father takes for his ulcer? Zantac? Xanax? Zenate?
  15. ↑ "Generic Zantac Marketing Pact". The New York Times . August 5, 1997. Retrieved July 4, 2022.
  16. ↑ Mary Duenwald (February 22, 2005). "Heartburn Relief, From Aciphex to Zantac". The New York Times . Retrieved July 4, 2022.
  17. ↑ Barnaby J. Feder (May 7, 1983). "GLAXO says Ulcer Drug has Approval of F.D.A." The New York Times . Retrieved July 4, 2022.
  18. ↑ Milt Freudenheim (September 8, 1995). "War on Heartburn Heats Up With Over-the-Counter Blitz". The New York Times . Retrieved July 4, 2022. A $200 million-plus marketing battle has started
  19. ↑ "RKS;ZANTAC ARRIVES WITH $100 MIL CAMPAIGN". Advertising Age . April 29, 1996.
  20. ↑ Nicholas Bakalar (June 11, 2019). "Heartburn Drugs Can Lead to Fatal Heart or Kidney Disease". The New York Times . Retrieved July 4, 2022.
  21. ↑ Christina Jewett (March 23, 2022). "Pfizer Recalls Some Blood Pressure Drugs, Citing Cancer Risk". The New York Times . Retrieved July 4, 2022.
  22. ↑ "Sanofi claws back some Zantac emails as privileged". Reuters. July 9, 2021.
  23. ↑ Jef Feeley (May 11, 2021). "Sanofi Accused of Destroying Emails Tied to Zantac Recall" . Retrieved July 4, 2022.
  24. ↑ Anthony Ramirez (November 5, 1995). "INVESTING IT;Will It Please the Court? A Litigation Analyst Calls the Verdicts". The New York Times . Retrieved July 4, 2022. buying the stock when it dips following negative litigation news
  25. ↑ "GSK Settles First Zantac Cancer Lawsuit Set for Trial in US". Bloomberg.com. 2023-06-23. Retrieved 2023-07-10.
  26. ↑ "GSK settles key Zantac cancer lawsuit". The Times . 2023-07-10. ISSN   0140-0460 . Retrieved 2023-07-10.
  27. ↑ "Walgreen Settles Suit On Pill-Switch Claims". The Wall Street Journal . June 5, 2008.
  28. ↑ "CVS Caremark Reaches Settlement". The Wall Street Journal . March 19, 2008.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.